IVERIC bio Inc

IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced the financial and operating results for the fiscal quarter ended September 30, 2020 and provided a general business update.

IVERIC bio Reports Third Quarter 2020 Operational Highlights and Financial Results

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced today that the Company will participate in upcoming virtual investor conferences in November.

IVERIC bio to Participate in Upcoming Virtual Investor / Industry Conferences

CTI BioPharma

Cerecor

Ligand Pharmaceuticals

Timothy P. Lynch's Stonepine Capital is a life science-focused hedge fund that seeks to utilize its industry experience to uncover undervalued and under-the-radar health companies. The fund takes a long-term approach to its small number of investments, which are focused on companies that have successfully commercialized products and which are in a strong financial position.

4 Health Stocks Stonepine Capital Loves (1 Has Gained 233% Since September 29)

NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced that it will report its third quarter 2020 financial and operating results on Monday, November 2, 2020.

IVERIC bio to Report Third Quarter 2020 Financial Results and Host Conference Call on Monday, November 2, 2020

IVERIC bio (ISEE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

IVERIC bio (ISEE) Catches Eye: Stock Jumps 6.8%

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced that the Company will participate in the two upcoming virtual investor conferences and a retina showcase conference in September.

IVERIC bio to Participate in Upcoming September Investor / Industry Conferences

NEW YORK--(BUSINESS WIRE)--IVERIC announced that the positive Phase 3 results from its GATHER1 clinical trial with Zimura® were published in Ophthalmology®.

IVERIC bio Announces Publication of GATHER1 Phase 3 Clinical Trial Results for Zimura® in Geographic Atrophy Secondary to Age-related Macular Degeneration, in Ophthalmology®, the Journal of the American Academy of Ophthalmology

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2020 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced the financial and operating results for the fiscal quarter ended June 30, 2020 and provided a general business update.

IVERIC bio Reports Second Quarter 2020 Operational Highlights and Financial Results

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced Pravin Dugel, MD will present an overview of the Company at the Wedbush PacGrow Healthcare Virtual Conference on Aug. 12, 2020.

IVERIC bio to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced that it will report its second quarter 2020 financial and operating results on Wednesday, August 5, 2020.

IVERIC bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Wednesday, August 5, 2020

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced the election of Mark S. Blumenkranz, M.D.

IVERIC bio Announces the Addition of Mark S. Blumenkranz, M.D.

IVERIC bio, Inc. (ISEE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: IVERIC bio

Rubius Therapeutics Inc

Zynerba Pharmaceuticals

Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma

Iveric Bio: Pick Up Post-Fundraising Low And Hold For Good News

An upsized public offering has investors increasingly confident about its prospects.

Why Iveric Bio Is Skyrocketing 24% Today

Shares of New York-based biopharma IVERIC bio Inc (NASDAQ: ISEE) were advancing strongly Monday morning on the back of a positive clinical readout.

Why Shares of Micro-Cap Biopharma IVERIC Bio Are Ripping Higher

NEW YORK, June 15, 2020 /PRNewswire/ -- IVERIC bio, Inc. (Nasdaq: ISEE) today announced positive 18 month results from the Company's first Phase 3 clinical trial (OPH2003) for Zimura® (avacincaptad pegol), a novel complement C5 inhibitor, for the treatment of geographic atrophy (GA)...

IVERIC bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings: Continuous Positive Treatment Effect with Favorable Safety Profile in Geographic Atrophy Secondary to Age-Related Macular Degeneration in a Phase 3 Trial

IVERIC bio (ISEE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why IVERIC bio (ISEE) Stock Might be a Great Pick

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2020 Results - Earnings Call Transcript

Investors need to pay close attention to IVERIC bio (ISEE) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in IVERIC bio (ISEE) Stock?

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q4 2019 Results - Earnings Call Transcript

Iveric bio: Much More Upside Ahead

Avid Bioservices

Endo International

IGM Biosciences Inc

Illumina

Kodiak Sciences Inc

Mylan

Neovasc

Pacira Pharmaceuticals

Pfizer

X4 Pharmaceuticals Inc

After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in their portfolio.

11 Biotechs and Pharma Stocks Being Given Huge Upside Targets for 2020

Iveric Bio Inc’s (NASDAQ: ISEE) lead asset, Zimura, could begin a pivotal clinical study in the geographic atrophy market in the quarter, according to Wedbush.

News for IVERIC bio Inc Stock (ISEE)